En poursuivant votre navigation sur ce site, vous acceptez le dépôt de cookies dans votre navigateur. (En savoir plus)
Portail > Offres > Offre UMR7311-KARPLE-001 - Chercheur/Post-Doc en chimie médicinale, Inhibiteurs de kinases (H/F)

Research chemist/Post-Doc in medicinal chemistry : synthesis of kinase inhibitors (M/F)

This offer is available in the following languages:
Français - Anglais

Date Limite Candidature : mardi 22 juin 2021

Assurez-vous que votre profil candidat soit correctement renseigné avant de postuler. Les informations de votre profil complètent celles associées à chaque candidature. Afin d’augmenter votre visibilité sur notre Portail Emploi et ainsi permettre aux recruteurs de consulter votre profil candidat, vous avez la possibilité de déposer votre CV dans notre CVThèque en un clic !

Faites connaître cette offre !

General information

Reference : UMR7311-KARPLE-001
Workplace : ORLEANS
Date of publication : Tuesday, June 1, 2021
Type of Contract : FTC Scientist
Contract Period : 13 months
Expected date of employment : 1 September 2021
Proportion of work : Full time
Remuneration : between 2648 and 3768 euros brut salary based on the experience level
Desired level of education : PhD
Experience required : 1 to 4 years

Missions

Synthesis of a library of kinase inhibitors pour in vitro, in cellulo, and in vivo studies on a milligram to gram scale for the most active compounds.

Activities

- small molecule synthesis
- reaction optimization
- product purification and characterization
- analysis of obtained results
- report writing

Skills

- experience in multi-step organic synthesis
- experience in heterocyclic chemistry
- experience in muti-scale synthesis

Work Context

The project will be carried out in the CNRS laboratory UMR 7311 at the Institute of Organic and Analytical Chemistry (ICOA, University of Orléans) in the "Heterocyclic chemistry for therapeutic and PET imaging innovation" group. Our research activity focuses on innovation in heterocyclic chemistry and engineering for translational medicine. The proposed CDD is part of the maturation project PELICAN (Preclinic Limk Cancer) financed by the FEDER and C-Valo.

We talk about it on Twitter!